Want to see TSE:MDNA full AI Analyst Report?
Total Valuation
Medicenna Therapeutics Corp has a market cap or net worth of C$30.66M. The enterprise value is C$18.12M.
Market CapC$30.66M
Enterprise ValueC$18.12M
Share Statistics
Medicenna Therapeutics Corp has 77,617,340 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding77,617,340
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Medicenna Therapeutics Corp’s return on equity (ROE) is -7.42 and return on invested capital (ROIC) is -725.41%.
Return on Equity (ROE)-7.42
Return on Assets (ROA)-2.18
Return on Invested Capital (ROIC)-725.41%
Return on Capital Employed (ROCE)-7.93
Revenue Per Employee0.00
Profits Per Employee-1.15M
Employee Count16
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Medicenna Therapeutics Corp is ―. Medicenna Therapeutics Corp’s PEG ratio is -0.06.
PE Ratio―
PS Ratio0.00
PB Ratio21.45
Price to Fair Value21.45
Price to FCF0.00
Price to Operating Cash Flow-1.84
PEG Ratio-0.06
Income Statement
In the last 12 months, Medicenna Therapeutics Corp had revenue of 0.00 and earned -18.41M in profits. Earnings per share was -0.22.
Revenue0.00
Gross Profit-77.00K
Operating Income-23.71M
Pretax Income-19.70M
Net Income-18.41M
EBITDA-23.63M
Earnings Per Share (EPS)-0.22
Cash Flow
In the last 12 months, operating cash flow was -17.92M and capital expenditures 9.44M, giving a free cash flow of -13.45M billion.
Operating Cash Flow-17.92M
Free Cash Flow-13.45M
Free Cash Flow per Share-0.17
Dividends & Yields
Medicenna Therapeutics Corp pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.53
52-Week Price Change-54.60%
50-Day Moving Average0.50
200-Day Moving Average0.89
Relative Strength Index (RSI)38.05
Average Volume (3m)30.62K
Important Dates
Medicenna Therapeutics Corp upcoming earnings date is Jul 31, 2026, Before Open (Confirmed).
Last Earnings DateJun 26, 2026
Next Earnings DateJul 31, 2026
Ex-Dividend Date―
Financial Position
Medicenna Therapeutics Corp as a current ratio of 1.52, with Debt / Equity ratio of 4.79%
Current Ratio1.52
Quick Ratio1.52
Debt to Market Cap<0.01
Net Debt to EBITDA0.26
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Medicenna Therapeutics Corp has paid -1.29M in taxes.
Income Tax-1.29M
Effective Tax Rate0.07
Enterprise Valuation
Medicenna Therapeutics Corp EV to EBITDA ratio is -1.99, with an EV/FCF ratio of 0.00.
EV to Sales0.00
EV to EBITDA-1.99
EV to Free Cash Flow0.00
EV to Operating Cash Flow-2.63
Balance Sheet
Medicenna Therapeutics Corp has C$6.25M in cash and marketable securities with C$119.00K in debt, giving a net cash position of C$6.13M billion.
Cash & Marketable SecuritiesC$6.25M
Total DebtC$119.00K
Net CashC$6.13M
Net Cash Per ShareC$0.08
Tangible Book Value Per ShareC$0.03
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Medicenna Therapeutics Corp is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-42.77%